These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

704 related items for PubMed ID: 15831602

  • 1. Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction.
    Weir R, McMurray JJ.
    Heart; 2005 May; 91 Suppl 2(Suppl 2):ii17-20; discussion ii31, ii43-8. PubMed ID: 15831602
    [Abstract] [Full Text] [Related]

  • 2. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    White HD, Aylward PE, Huang Z, Dalby AJ, Weaver WD, Barvik S, Marin-Neto JA, Murin J, Nordlander RO, van Gilst WH, Zannad F, McMurray JJ, Califf RM, Pfeffer MA, VALIANT Investigators.
    Circulation; 2005 Nov 29; 112(22):3391-9. PubMed ID: 16301343
    [Abstract] [Full Text] [Related]

  • 3. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
    Azadpour M, Lamas GA.
    Expert Rev Cardiovasc Ther; 2004 Nov 29; 2(6):891-902. PubMed ID: 15500434
    [Abstract] [Full Text] [Related]

  • 4. Improving outcomes in post-acute myocardial infarction heart failure: incorporation of aldosterone blockade into combination therapy to optimize neurohormonal blockade.
    Pitt B, Fonarow GC, Gheorghiade M, Deedwania PC, Duprez DA.
    Am J Cardiol; 2006 May 22; 97(10A):26F-33F. PubMed ID: 16698332
    [Abstract] [Full Text] [Related]

  • 5. [Recent advances and limitations of medical treatment on heart failure].
    Momomura S.
    Kyobu Geka; 2007 Jun 22; 60(6):484-7. PubMed ID: 17564066
    [Abstract] [Full Text] [Related]

  • 6. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
    McMurray JJ, Pfeffer MA, Swedberg K, Dzau VJ.
    Circulation; 2004 Nov 16; 110(20):3281-8. PubMed ID: 15545527
    [No Abstract] [Full Text] [Related]

  • 7. Lessons from the management of chronic heart failure.
    McDonagh TA.
    Heart; 2005 May 16; 91 Suppl 2(Suppl 2):ii24-7; discussion ii31, ii43-8. PubMed ID: 15831605
    [Abstract] [Full Text] [Related]

  • 8. Heart failure: recent advances in prevention and treatment.
    Fonarow GC.
    Rev Cardiovasc Med; 2000 May 16; 1(1):25-33, 54. PubMed ID: 12457149
    [Abstract] [Full Text] [Related]

  • 9. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
    Califf RM, Lokhnygina Y, Velazquez EJ, McMurray JJ, Leimberger JD, Lewis EF, Diaz R, Murin J, Pfeffer MA.
    Am J Cardiol; 2009 Jul 15; 104(2):151-7. PubMed ID: 19576338
    [Abstract] [Full Text] [Related]

  • 10. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
    Prescrire Int; 2006 Apr 15; 15(82):46-9. PubMed ID: 16604728
    [Abstract] [Full Text] [Related]

  • 11. Pharmacologic therapies across the continuum of left ventricular dysfunction.
    Abraham WT, Greenberg BH, Yancy CW.
    Am J Cardiol; 2008 Sep 08; 102(5A):21G-28G. PubMed ID: 18722188
    [Abstract] [Full Text] [Related]

  • 12. [Treatment of heart failure based on large-scale clinical trials: renin-angiotensin system antagonists and beta-blockers].
    Kubota T, Takeshita A.
    Nihon Rinsho; 2003 May 08; 61(5):801-6. PubMed ID: 12755006
    [Abstract] [Full Text] [Related]

  • 13. Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?
    Ghanem FA, Movahed A.
    Rev Cardiovasc Med; 2005 May 08; 6(4):206-13. PubMed ID: 16379016
    [Abstract] [Full Text] [Related]

  • 14. [Temporal trends in pharmacological therapy in the IN-CHF registry from 1995 to 2005].
    Fabbri G, Gorini M, Maggioni AP, Di Lenarda A, Area Scompenso ANMCO, Firenze.
    G Ital Cardiol (Rome); 2007 Feb 08; 8(2):102-6. PubMed ID: 17402354
    [Abstract] [Full Text] [Related]

  • 15. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 08; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 16. Potential novel pharmacological therapies for myocardial remodelling.
    Landmesser U, Wollert KC, Drexler H.
    Cardiovasc Res; 2009 Feb 15; 81(3):519-27. PubMed ID: 19019834
    [Abstract] [Full Text] [Related]

  • 17. Mechanistic and clinical rationales for using beta-blockers in heart failure.
    Bristow MR.
    J Card Fail; 2000 Jun 15; 6(2 Suppl 1):8-14. PubMed ID: 10908093
    [Abstract] [Full Text] [Related]

  • 18. [Chronic left heart failure. A focus on the pathogenetic basis of medical treatment].
    Novosel MK, Haghfelt TH.
    Ugeskr Laeger; 2006 May 08; 168(19):1854-6. PubMed ID: 16756801
    [Abstract] [Full Text] [Related]

  • 19. From left ventricular dysfunction to heart failure.
    Cleland JG.
    Arch Mal Coeur Vaiss; 1996 Nov 08; 89(11):1397-402. PubMed ID: 9092398
    [Abstract] [Full Text] [Related]

  • 20. [ACE inhibitors and angiotensin II receptor antagonists in acute coronary syndrome].
    Milicić D.
    Acta Med Croatica; 2004 Nov 08; 58(2):129-34. PubMed ID: 15208798
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.